Page 6 - Oncocyte Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncocyte inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncocyte Inc Today - Breaking & Trending Today

OncoCyte (NASDAQ:OCX) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report issued on Monday. The brokerage issued a sell rating on the stock. OCX has been the topic of several other reports. Needham & Company LLC reduced their price target on OncoCyte from $9.00 to $4.25 and set a buy rating on […] ....

United States , Raymond James Financial Services Advisors Inc , Goldman Sachs Group Inc , Cubist Systematic Strategies , Oncocyte Corporation , Needham Company , Free Report , Get Free Report , James Financial Services Advisors , Sachs Group , Systematic Strategies , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a report released on Tuesday morning. The firm issued a sell rating on the stock. OCX has been the topic of a number of other research reports. Needham & Company LLC decreased their price objective on shares of OncoCyte from $9.00 to $4.25 […] ....

United States , Geode Capital Management , Oncocyte Corporation , Renaissance Technologies , Investment Company Inc , Needham Company , Balyasny Asset Management , Defender Capital , Free Report , Get Free Report , Capital Management , Asset Management , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

OncoCyte (NASDAQ:OCX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research note released on Saturday morning. The brokerage issued a sell rating on the stock. A number of other brokerages have also recently commented on OCX. Benchmark reduced their price objective on OncoCyte from $9.00 to $5.00 and set a speculative buy […] ....

United States , Oncocyte Corporation , Goldman Sachs Group Inc , Raymond James Financial Services Advisors Inc , Needham Company , Cubist Systematic Strategies , Free Report , Get Free Report , James Financial Services Advisors , Sachs Group , Systematic Strategies , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX)

StockNews.com assumed coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report sent to investors on Saturday morning. The brokerage issued a sell rating on the stock. Several other research analysts also recently commented on the company. Needham & Company LLC reduced their price objective on OncoCyte from $9.00 to $4.25 and […] ....

United States , Vanguard Group Inc , Geode Capital Management , Defender Capital , Needham Company , Millennium Management , Oncocyte Corporation , Investment Company Inc , Free Report , Get Free Report , Capital Management , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,

OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX – Free Report) in a research report report published on Sunday morning. The brokerage issued a sell rating on the stock. OCX has been the topic of a number of other reports. Benchmark reduced their price target on shares of OncoCyte from $9.00 to $5.00 and set […] ....

United States , Defender Capital , Millennium Management , Oncocyte Corporation , Needham Company , Investment Company Inc , Geode Capital Management , Vanguard Group Inc , Free Report , Get Free Report , Capital Management , Cyte Corporation , Oncocyte Daily , Nasdaq Ocx , Initiated Coverage , Stocknews Com ,